Fusion protein Ag85B-MPT64190-198-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice

Vaccine

Volumn 27, Issue 44, 2009, Pages 6179-6185

  Luo, Yu ^a,b   Wang, Bingxiang ^c   Hu, Lina ^c   Yu, Hongjuan ^a   Da, Zejiao ^a   Jiang, Wenwen ^a   Song, Nannan ^a   Qie, Yaqing ^d   Wang, Honghai ^d   Tang, Zhijiao ^e   Xian, Qiaoyang ^e   Zhang, Ying ^a,f   Zhu, Bingdong ^a  

^a Institute of Pathogenic Biology   (China)

^b LANZHOU UNIVERSITY   (China)

^c LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^d FUDAN UNIVERSITY   (China)

^e WUHAN UNIVERSITY   (China)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

BCG; Fusion protein; Mycobacterium tuberculosis; Polysaccharide nucleic acid adjuvant; Prime boost; Subunit vaccine

Indexed keywords

ANTIGEN 85B; BACTERIAL POLYSACCHARIDE; BCG POLYSACCHARIDE NUCLEIC ACID; BCG VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FUSION PROTEIN AG85B MPT64[190-198] MTB8.4; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLEEN CELL; TUBERCULOSIS;

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS; VACCINES, SUBUNIT;

EID: 70349778463     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.018     Document Type: Article

References (21)

1. Anonymous. Global tuberculosis control-surveillance, planning, financing, WHO report, 1 (2006), World Health Organization, Geneva, Switzerland
2. World Health Organization. Tuberculosis-Fact Sheet104 (2007). http://www.who.int/mediacentre/factsheets
3. Onyebujoh P., and Rook G.A. Tuberculosis Nature Reviews Microbiology 2 (2004) 930-932
4. Brewer T.F. Preventing tuberculosis with Bacillus Calmette Guerin vaccine: a meta-analysis of the literature. Clinical Infectious Diseases 31 Suppl. (3) (2000) 64-67
5. Gupta U.D., Katoch V.M., and McMurray D.N. Current status of TB vaccines. Vaccine 25 (2007) 3742-3751
6. Palomino JC, Leão SC, Ritacco V, Tuberculosis 2007 From basic science to patient care. In: Carlos M, Fabiana B, Brigitte G, editors, New vaccines against tuberculosis, www.TuberculosisTextbook.com, 341-60.
7. Logan K.E., Chambers M.A., Hewinson R.G., and Hogarth P.J. Frequency of IFN-γ producing cells correlates with adjuvant enhancement of bacille Calmette-Guérin induced protection against Mycobacterium bovis. Vaccine 23 (2005) 5526-5532
8. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 (2006) 5452-5460
9. Okkels L.M., Doherty T.M., and Andersen P. Selecting the components for a safe and efficient tuberculosis subunit vaccine-recent progress and post-genomic insights. Current Pharmaceutical Biotechnology 4 (2003) 69-83
10. Sable1SB, Kalra M., Verma I., and Khuller G.K. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clinical Immunology 122 (2007) 239-251
11. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews 199 (2004) 201-216
12. Fonseca D.M., Silva C.L., Paula M.O., Soares E.G., Marchal G., Horn C., et al. Increased levels of interferon-γ primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 121 (2007) 508-517
13. Zhang Y. Immunopathogenesis of tuberculosis: implications for vaccine development. Respirology 13 Suppl. (3) (2008) 81-87
14. Zhu B., Qie Y., Wang J., Zhang Y., Wang Q., Xu Y., et al. Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. European Journal of Pharmaceutics and Biopharmaceutics 66 (2007) 318-326
15. Lai K., Sun B., and Zhong N. Effect of BCG-PSN on TH1 aim TH2 cytokine responses of peripheral blood mononuclear cells from atopic asthmatics. China Journal Microbiology and Immunology 25 (2005) 481-484
16. Demissie A., Ravn P., Olobo J., Doherty T.M., Eguale T., Geletu M., et al. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infection and Immunity 67 (1999) 5967-5971
17. Orme I.M. Current progress in tuberculosis vaccine development. Vaccine 23 (2005) 2105-2108
18. Bai Y., Xue Y., Gao H., Wang L., Ding T., Bai W., et al. Expression and purification of Mycobacterium tuberculosis ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model. Protein Expression and Purification 59 (2008) 195
19. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infection and Immunity 11 (2004) 6622-6632
20. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. The Journal of Immunology 171 (2003) 1602-1609
21. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. American Journal of Respiration and Critical Care Medicine 15 179 (2009) 724-733